SAN FRANCISCO — Aimmune Therapeutics CEO Jayson Dallas would be enjoying his time at the J.P. Morgan Healthcare Conference a lot more this week if the U.S. government were open for business. Instead, in between meetings with investors and other health care folks, Dallas is being forced to monitor D.C. gridlock because his company’s experimental treatment to protect people against peanut allergy is in FDA limbo.
“It’s frustrating,” Dallas said in an interview Tuesday during JPM Week.
About the Author Reprints
There is an upside then
stopping biomedical scams from being validated. Unfortunate, in reality, it is just a slow down